Prof. Baas and his team found that inhibition of the terminal pathway facilitates regeneration. Many neurodegenerative diseases show activation of the complement system. In some diseases complement activation can already be found in the initial stages of disease.
Based on these discoveries Complement Pharma is developing new treatments for neurodegenerative disorders. The Complement Pharma antibodies are directed to C6, an essential component of the MAC. These antibodies will lower the level of C6 in the human body, prevent MAC formation and thus might delay nerve degeneration and even accelerates nerve regeneration.